All Online

1 - 8 of 8 results

Refine

Active filters

Menopause and Hormone Therapy
1 CME CREDIT

Information reaches clinicians at a fast and furious pace. This session will help you keep up with a review of some recent literature that impacts the health of women and other individuals. During this session, the faculty will discuss recent findings on the following topics: hormonal therapy and cancer risk, the role of testosterone in women’s health, HPV immunizations and rates of cervical cancer, and prevention strategies for breast cancer, including chemo prophylaxis for high risk individuals, guidelines for BRCA screening, and comparison of various mammography recommendations. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on February 7, 2020 and they are subject to change as new information is published.


1 CME CREDIT

Initial findings of the Women’s Health Initiative (WHI) published in 2002 forever changed the way menopause hormone therapy has been viewed in the United States. After WHI, use of systemic menopause hormone therapy (MHT) decreased by as much as 80 percent among U.S. women. In the following decade and half, additional data derived from WHI coupled with new research findings resulted in confusion and misunderstandings for patients and clinicians alike on the appropriate use of MHT to manage menopause. This presentation will blend the findings of WHI with newer learnings and provide a practical approach to using MHT.


0.75 CME CREDIT

This talk will update participant knowledge about hormone therapy for menopause, focusing on our current understanding of the myths, benefits, and harms of treatment. The myth that hormone therapy is, in general, harmful, is based on data looking at the consequences of hormone therapy in individuals aged 60 and older. In contrast, the data on most individuals who are either under age 60 or less than 10 years from menopause show that the benefits appear to outweigh the risks. A clinical practice guideline published by the Endocrine Society recommends an individualized approach to treatment based on calculating baseline cardiovascular and breast cancer before initiating therapy. The benefits of hormone therapy for menopause include management of hot flashes and vaginal atrophy. It is not recommended for the prevention of cardiovascular disease, osteoporosis, or dementia. In the Women’s Health Initiative combined hormone therapy trial, risks included coronary events, stroke, venous thromboembolism, and breast cancer. No increase in either coronary heart disease or breast cancer risk was seen with unopposed estrogen. These results suggest that the progestin played an important role in the increased coronary and breast cancer risk seen with combined therapy.


0.75 CME CREDIT

Using a case-based approach, the speaker will discuss the current state of menopausal hormone therapy and management strategies for patients who are not candidates for hormonal options. This talk will provide audience members with a review of recent publications that impact the management of patients’ menopausal symptoms.


0.75 CME CREDIT

This talk will update clinicians with the latest studies and guidelines statements about treatment of menopause. Information on systemic and local hormonal therapies, non-hormonal pharmacological therapies, and complementary and alternative therapies will enable clinicians to provide their patients experiencing menopause systems with an array of options.


1 CME CREDIT

Information reaches clinicians at a fast and furious pace. This session will help you keep up with a review of some recent literature that impacts the health of women and other individuals. During this session, the faculty will discuss recent findings on the following topics: hormonal therapy and cancer risk, the role of testosterone in women’s health, HPV immunizations and rates of cervical cancer, and prevention strategies for breast cancer, including chemo prophylaxis for high risk individuals, guidelines for BRCA screening, and comparison of various mammography recommendations.


0.75 CME CREDIT

Participate in this activity to get the most up-to-date information about menopause, systemic hormone therapy, and alternative treatment options to individualize and optimize care of your patients.


1 CME CREDIT

Although women make up a majority of the population and typically the majority of primary care providers patient panel, it is well established that many gender specific needs of women, such as menopause and sexual health, are neglected, in part due to lack of women’s health education in these areas. In today’s panel, 3 women’s health experts will discuss 3 women’s health cases that highlight current data and best practice for management of early menopause, GSM, and women known to carry a genetic mutation that elevates their risk of breast and ovarian cancer.